Exam 1 - Random Info Flashcards by Rehman Hameed

6-MP polymorphism

TPMT loss of function

How well did you know this?

Not at all

Perfectly

cytarabine synergy agent

a. leucovorin
b. tetrahydrouridine
c. dexrazoxane
d. 5-FU

b. tetrahydrouridine

How well did you know this?

Not at all

Perfectly

cisplatin toxicity

nephrotoxicity

How well did you know this?

Not at all

Perfectly

irinotecan polymorphism

a. TPMT
b. UGT1A1
c. BRAF-V600
d. T315l

b. UGT1A1

How well did you know this?

Not at all

Perfectly

drug given with doxorubicin to protect against anthracycline-induced cardiotoxicity

dexrazoxane

How well did you know this?

Not at all

Perfectly

bleomycin main toxicity

pulmonary

How well did you know this?

Not at all

Perfectly

which has a lower rate of neurotoxicity?

a. vincristine
b. eribulin

b. eribulin

How well did you know this?

Not at all

Perfectly

formulation for GnRH analogs for breast cancer (i.e. leuprolide)

depot

How well did you know this?

Not at all

Perfectly

which drug does not result in “flare” of testosterone production?

a. leuprolide
b. goserelin
c. triptorelin
d. degarelix

d. degarelix

How well did you know this?

Not at all

Perfectly

common SE of abiraterone

inc cholesterol levels

How well did you know this?

Not at all

Perfectly

what drug inhibits the function of 17 alpha-hydroxylase and C17,20 lyase?

a. abiraterone
b. fulvestrant
c. exemestane
d. alectinib

a. abiraterone

How well did you know this?

Not at all

Perfectly

drug that can inhibit the “gatekeeper” T315l mutation

a. alectinib
b. quizartinib
c. ponatinib
d. dabrafenib

c. ponatinib

How well did you know this?

Not at all

Perfectly

drug that is specific for internal tandem duplication (ITD) mutations

a. sirolimus
b. alectinib
c. quizartinib
d. trametinib

c. quizartinib

How well did you know this?

Not at all

Perfectly

which drug inhibits immune response by blocking IL-2 signaling transduction?

a. sirolimus
b. dabrafenib
c. trametinib
d. afatinib

a. sirolimus

How well did you know this?

Not at all

Perfectly

which drug is a type III allosteric kinase inhibitor?

a. gefitinib
b. alectinib
c. trametinib
d. acalabrutinib

c. trametinib

How well did you know this?

Not at all

Perfectly

what drug is used in combo with trametinib for BRAFV600E mutant metastatic melanoma?

dabrafenib

How well did you know this?

Not at all

Perfectly

kinase inhibitor that is effective for T790M mutation

a. trametinib
b. lapatinib
c. tucatinib
d. osimertinib

d. osimertinib

How well did you know this?

Not at all

Perfectly

drug that is EGFR and HER2 reversible inhibitor

lapatinib

How well did you know this?

Not at all

Perfectly

which antibody is it mentioned that there is ~3% severe infusion reaction?

cetuximab

antibody that targets VEGF

bevacizumab

antibody that targets VEGF receptor

a. ipilimumbab
b. ramucirumab
c. daratumumab
d. rituximab

b. ramucirumab

antibody that binds CD20 only to inhibit B-cell proliferation

a. ipilimumbab
b. ramucirumab
c. daratumumab
d. rituximab

d. rituximab

antibody that targets CD38, a protein highly expressed on plasma B cells that make antibodies

a. ipilimumbab
b. ramucirumab
c. daratumumab
d. rituximab

c. daratumumab

antibody that targets CTLA-4 receptor and has a severe inflammatory response

a. ipilimumab
b. ramucirumab
c. daratumumab
d. rituximab

a. ipilimumab

antibody that binds PD-1 receptor expressed on T-cells a. atezolizumab b. pembrolizumab c. trastuzumab emtansine d. teclistamab

b. pembrolizumab

antibody that binds PD-L1 receptor expressed on macrophages and tumor cells a. atezolizumab b. pembrolizumab c. trastuzumab emtansine d. teclistamab

a. atezolizumab

mouse, chimeric, humanized, and fully human

mouse = o chimeric = xi humanized = zu fully human = u

two antibody-drug conjugates to know

-trastuzumab emtansine -trastuzumab deruxtecan

trastuzumab emtansine: what is emtansine's role?

inhibits microtubule assembly

SE of emtansine (2 of them)

thrombocytopenia, hepatotoxicity

which BiTE binds to CD3 and brings activated T-cell into proximity of CD19? a. blinatumomab b. mosunetuzumab c. teclistamab d. taquetamab

a. blinatumomab

which BiTE targets CD3 and CD20? a. blinatumomab b. mosunetuzumab c. teclistamab d. taquetamab

b. mosunetuzumab

which BiTE targets CD3 on T cells and B-cell maturation antigen (BCMA) on multiple myeloma cells? a. blinatumomab b. mosunetuzumab c. teclistamab d. taquetamab

c. teclistamab

which BiTE targets CD3 on T cells and human G-protein coupled receptor family C group 5 member D (GPRC5D) on multiple myeloma cells? a. blinatumomab b. mosunetuzumab c. teclistamab d. taquetamab

d. taquetamab

which class of drugs causes cytokine release syndrome?

BiTE's

PD-1 is expressed on which of the following? SELECT ALL THAT APPLY a. T-cells b. macrophages c. tumor cells

a. T-cells

PD-L1 is expressed on which of the following? SELECT ALL THAT APPLY a. T-cells b. macrophages c. tumor cells

b. macrophages c. tumor cells

goal of Sipulcel-T (Provenge)

to stimulate a pt's own immune system to attack the cancer

which agent is a PAP-GM-CSF?

Sipulcel-T (Provenge)

target for CAR-T therapies from class

CD19

Sipulcel-T can cause flu-like symptoms and a possible inc risk of ______

stroke

The antibody Fakeumab has just entered the market. What type of the antibody was it? a. Fully human b. Humanized c. Fully mouse d. Chimeric

a. Fully human

Which antibody is effective against metastatic melanoma and targets CTLA-4? a. Ipilimumab b. Trastuzumab c. Daratumumab d. Blinatumomab

a. Ipilimumab

Which of the following proteins is used as a cancer biomarker test to determine eligibility for treatment of NSCLC with pemrolizumab? a. CD19 b. CTLA4 c. PDL1 d. PD1

c. PDL1

Which of the following antigens is a common target for CAR-T therapy in B cell malignancy? A) CD4 B) CD19 C) CD28 D) CTLA4

B) CD19

What is the primary mechanism of action of bispecific T cell engagers in cancer immunotherapy? A) They inhibit the PD1/PDL1 interaction B) They bring T cells and cancer cells in close proximity to facilitate T cell mediated cytotoxicity C) They stimulate the innate immune system to recognize tumor cells. D) They increase neoantigens.

B) They bring T cells and cancer cells in close proximity to facilitate T cell mediated cytotoxicity